GLP-1 Drugs: Benefits Reverse After Stopping Semaglutide, Study Finds
Recent studies are delivering sobering news for individuals using medications based on semaglutide. These drugs, belonging to the GLP-1 class – including Ozempic, Wegovy, and Rybelsus – have been widely touted for benefits extending beyond weight loss and diabetes treatment, potentially reducing risks associated with cardiovascular disease and even cognitive decline. But, emerging research suggests these benefits may be surprisingly fragile and quickly lost upon discontinuation of the medication.
A study published in the BMJ Medicine journal and highlighted by Futurism, analyzed the medical data of over 333,000 adults with diabetes over a three-year period. Approximately one-third of these patients were treated with a GLP-1 medication, such as Ozempic, which contains semaglutide as its active ingredient. The research revealed that patients consistently taking the medication for three years experienced an 18% reduction in the risk of cardiovascular events, reinforcing existing evidence of the drugs’ broader health benefits.
However, the study also found a significant increase in cardiovascular risk when treatment was interrupted. Even a relatively short pause of six months raised the risk of a major cardiovascular event by as much as 8%. For those who discontinued treatment for one or two years, the risk increase climbed to 22%, effectively negating the protective effects previously gained from the medication. Washington University School of Medicine epidemiologist Ziyad Al-Aly described this phenomenon as a “metabolic shock,” stating, “It takes years to build cardiovascular protection, but much less time to lose it,” in an interview with CNBC.
Beyond cardiovascular risks, cessation of semaglutide treatment often leads to weight regain as appetite returns. Al-Aly emphasized that other effects also emerge, including the reappearance of inflammation, increases in blood pressure, and elevated cholesterol levels. The study suggests that these interruptions may leave lasting impacts, as patients do not fully recover the initial benefits of the medication even upon restarting treatment.
Here’s particularly concerning given the high rates of treatment discontinuation and interruption. During the study period, 26% of patients stopped using the medication altogether, while 23% experienced pauses of at least six months before resuming. According to Drugs.com, semaglutide is a GLP-1 agonist that regulates appetite and blood sugar.
Challenges surrounding GLP-1 medications extend beyond the loss of benefits upon discontinuation. Common side effects, such as nausea, affect approximately half of patients at the beginning of treatment, with less frequent occurrences of vomiting and diarrhea also reported. High demand coupled with limited production frequently leads to shortages of these medications in pharmacies. MedLife reports that semaglutide is available under different forms and concentrations, including Ozempic for type 2 diabetes, Wegovy for obesity, and Rybelsus as an oral option for diabetes.
The availability of different forms of semaglutide – injectable Ozempic and Wegovy, and oral Rybelsus – offers varying administration methods, but the underlying concern regarding sustained benefit remains. Medicaldex.ro notes that semaglutide acts as an agonist to the GLP-1 receptor, improving glycemic control and aiding in weight management.